Figure 1. Results of laboratory testing at the first visit were as follows: (A) bone marrow smear showing cellular proliferation; (B) coronal and sagittal CT revealing splenomegaly, but no lymphadenopathy is observed; (C) flow cytometry showing tumor cells positive for CD2, CD3, CD5, CD7, and CD52 but negative for CD1, CD4, CD8, CD13, CD16, CD19, CD25, CD30, CD34, CD56, CD57, and HLA-DR. G-banding revealed complex chromosomal rearrangements. (D) CD52 in lymphocytes decreased to an extremely low level (4.0%) during relapse.
From: Methotrexate, Hydrocortisone, Vincristine, Sobuzoxane, and Etoposide Is an Effective Option for Relapsed T-cell Prolymphocytic Leukemia with Loss of CD52 Expression after Retreatment with Alemtuzumab
